Nisa Investment Advisors LLC reduced its stake in The Cooper Cos. (NYSE:COO) by 0.3% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 37,810 shares of the medical device company’s stock after selling 100 shares during the period. Nisa Investment Advisors LLC owned about 0.08% of The Cooper Cos. worth $6,778,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. Eqis Capital Management Inc. acquired a new position in The Cooper Cos. during the second quarter valued at $876,000. Legacy Private Trust Co. boosted its position in The Cooper Cos. by 2.1% in the second quarter. Legacy Private Trust Co. now owns 3,365 shares of the medical device company’s stock valued at $577,000 after buying an additional 70 shares in the last quarter. Beacon Financial Group boosted its position in The Cooper Cos. by 67.4% in the second quarter. Beacon Financial Group now owns 4,489 shares of the medical device company’s stock valued at $762,000 after buying an additional 1,807 shares in the last quarter. Fisher Asset Management LLC boosted its position in The Cooper Cos. by 14.8% in the second quarter. Fisher Asset Management LLC now owns 106,914 shares of the medical device company’s stock valued at $19,469,000 after buying an additional 13,800 shares in the last quarter. Finally, Loring Wolcott & Coolidge Fiduciary Advisors LLP MA boosted its position in The Cooper Cos. by 2.6% in the second quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA now owns 17,615 shares of the medical device company’s stock valued at $3,022,000 after buying an additional 440 shares in the last quarter. 98.06% of the stock is currently owned by institutional investors and hedge funds.

Institutional Ownership by Quarter for The Cooper Cos. (NYSE:COO)

The Cooper Cos. (NYSE:COO) traded down 3.33% during mid-day trading on Wednesday, hitting $164.48. The company had a trading volume of 849,141 shares. The firm’s 50 day moving average is $176.26 and its 200 day moving average is $175.93. The company has a market capitalization of $8.02 billion, a price-to-earnings ratio of 32.21 and a beta of 0.62. The Cooper Cos. has a 52 week low of $119.28 and a 52 week high of $190.99.

The Cooper Cos. (NYSE:COO) last posted its quarterly earnings data on Thursday, September 1st. The medical device company reported $2.30 earnings per share for the quarter, beating the Zacks’ consensus estimate of $2.29 by $0.01. The Cooper Cos. had a return on equity of 14.89% and a net margin of 13.14%. The company earned $514.70 million during the quarter. During the same period last year, the business earned $1.97 EPS. The firm’s quarterly revenue was up 11.5% on a year-over-year basis. On average, equities research analysts predict that The Cooper Cos. will post $8.43 EPS for the current year.

TRADEMARK VIOLATION WARNING: This piece of content was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece of content on another website, it was stolen and republished in violation of US & international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://www.thecerbatgem.com/2016/11/30/the-cooper-cos-coo-shares-sold-by-nisa-investment-advisors-llc.html.

Several research firms have weighed in on COO. Stifel Nicolaus reissued a “buy” rating and issued a $215.00 price objective on shares of The Cooper Cos. in a research report on Friday, September 9th. Jefferies Group boosted their price objective on The Cooper Cos. from $190.00 to $210.00 and gave the stock a “buy” rating in a research report on Wednesday, August 24th. BMO Capital Markets boosted their price objective on The Cooper Cos. from $199.00 to $206.00 and gave the stock an “outperform” rating in a research report on Friday, September 2nd. Wells Fargo & Co. reissued a “hold” rating on shares of The Cooper Cos. in a research report on Sunday, September 11th. Finally, Zacks Investment Research cut The Cooper Cos. from a “buy” rating to a “hold” rating in a research report on Friday, August 5th. Four research analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. The Cooper Cos. currently has a consensus rating of “Buy” and an average price target of $187.80.

In other The Cooper Cos. news, EVP Albert G. White III sold 20,000 shares of the stock in a transaction on Wednesday, September 14th. The stock was sold at an average price of $185.72, for a total transaction of $3,714,400.00. Following the sale, the executive vice president now directly owns 41,639 shares in the company, valued at approximately $7,733,195.08. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director William A. Kozy bought 270 shares of the business’s stock in a transaction on Tuesday, September 6th. The shares were acquired at an average price of $186.69 per share, for a total transaction of $50,406.30. Following the completion of the purchase, the director now owns 770 shares in the company, valued at approximately $143,751.30. The disclosure for this purchase can be found here. Corporate insiders own 2.20% of the company’s stock.

About The Cooper Cos.

The Cooper Companies, Inc (Cooper) is a medical device company. The Company operates through two business units: CooperVision, Inc (CooperVision) and CooperSurgical, Inc (CooperSurgical). CooperVision develops, manufactures and markets a range of soft contact lenses for the vision correction market. CooperVision offers Biofinity monthly spherical, toric and multifocal lenses under the Avaira brand.

5 Day Chart for NYSE:COO

Receive News & Stock Ratings for The Cooper Cos. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for The Cooper Cos. and related stocks with our FREE daily email newsletter.